Loading data for VRTX — first visit, this takes a few seconds.

アラート

Vertex Pharmaceuticals (VRTX)

NasdaqGS: VRTX · リアルタイム株価 · USD

552.06

+23.87 (4.52%)

終値時点： Aug 19, 2026, 8:00 PM

550.10

-0.36%

時間外: 7:59 PM

4.52% (1D)

データがありません

買気配	544.38
時価総額	139.93B
売上高（TTM）	12.59B
純利益（TTM）	4.41B
ベータ	0.30
EPS（TTM）	17.17
PER（TTM）	32.15
予想PER	25.31
PBR（TTM）	6.91
PSR（TTM）	11.11
Earnings Date	Nov 2, 2026

売気配	545
出来高	1,437,126
平均出来高（20日）	1,567,301
始値	534.72
前日終値	528.19
当日レンジ	532.88 - 553.69
52週レンジ	374.17 - 553.69
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

VRTXについて

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Jul 24, 1991

従業員数 6,400

上場取引所 NasdaqGS

ティッカー VRTX

ウェブサイト https://www.vrtx.com

企業情報の全文

業績

2025年のVertex Pharmaceuticalsの売上高は12Bで、前年の11.02Bから8.9%の増加でした。利益は3.95Bで、-838.09%の減少でした。

財務諸表

決算サプライズ

Vertex PharmaceuticalsはAug 3, 2026に四半期決算を発表しました：

売上高は $3.33B で、予想を下回りました $0, うち 12.45% の前年比増加にあたります.

EPSは 4.73 で、予想を下回りました -0.02, うち 4.65% の前年比増加にあたります.

次回決算発表

Vertex Pharmaceuticalsの決算発表予定日は Nov 2, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1日前 · StockStory

3 Cash-Producing Stocks on Our Watchlist

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

5日前 · Insider Monkey

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

5日前 · Simply Wall St.

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent n...

5日前 · Motley Fool

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The drugmaker should significantly mitigate its most important risk as it develops new products.

5日前 · Simply Wall St.

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurch...

2ページ中1ページ

Vertex Pharmaceuticals (VRTX)